Rapid Nutrition Partners with Tismore to Launch New Immune Support Formula
London, United Kingdom – 9 August 2022 - Rapid Nutrition PLC (Euronext Growth: ALRPD, OTCQB: RPNRF), a natural healthcare company focused on sports nutrition, diet management and life science products with extensive worldwide distribution, Australian subsidiary is partnering with leading Australian manufacturer Tismore to commence the first production run of its patented immunity support formula. The natural immunity support formula Azurene is an anti-inflammatory formula that may aid in relieving cold and flu symptoms and also supports circulation and eye health.
The herbal formula, with ingredients traditionally used in European herbal medicine to treat colds and flus, is the result of several years of extensive research, including in-vitro testing, scholarly literature and clinical trials. Previously, Rapid Nutrition was awarded an Innovation Connections grant to further develop and commercialize the formula.
“Tismore excels in their support for a variety of global pharma companies which include Sanofi and GSK, making them our ideal partner for this remarkable venture,” said Rapid Nutrition CEO Simon St. Ledger. “We look forward to offering our shareholders early access to the formula prior to its global launch and sharing this significant development with the world.”
The first phase of the project will include product launch later this year; Azurene will initially be sold as a sachet that consumers can mix with water. In 2023, line extensions and production will expand to include effervescent tablets, capsules and, eventually, a full family of products that use the Azurene base formula. The versatile evidence-based formula, which is safe for all ages, can be made into lozenges, tablets, capsules and powders.
Shareholders interested in signing up for the waiting list for Azurene can do so at www.rnplc.com
About Rapid Nutrition
Dedicated to the development and distribution of premium, science-based health and wellness brands across the globe, Rapid Nutrition shares a wealth of award-winning products with consumers who are passionate about innovations that are “made by nature, refined by science.” Rapid Nutrition’s first-class scientific team matches the experience of its management team to keep both the company and consumers on top of the latest industry trends and developments, while aligning with industry leaders worldwide to deliver effective supplements and solutions. Rapid Nutrition aims to be the supplier of choice globally by offering premium brands with the highest-quality ingredients to deliver maximum results.
For more information, please visit http://rnplc.com
Investor Relations Contact:
This press release contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and or otherwise that involve risks, uncertainties and assumptions that could cause Rapid Nutrition PLCs actual results and experience to differ materially from anticipated results and expectations expressed in these forward-looking statements. Rapid Nutrition PLC has in some cases identified forward-looking statements by using words such as "anticipates," "believes," "hopes," "estimates," "looks," "expects," "plans," "intends," "goal," "potential," "may," "suggest," and similar expressions. Rapid Nutrition PLC undertakes no obligation to release publicly the results of any revisions to any such forward-looking statements that may be made to reflect events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events, except as required by applicable law or regulation.
This media information does not constitute an offer to sell, or a solicitation of an offer to buy, any securities. This information does not constitute an offering prospectus within the meaning within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of 14 of June 2017 on the prospectus to be published when securities are offered to the public or admitted to trading on a regulated market, and repealing Directive 2003/71 or a listing prospectus within the meaning of the listing rules of the Euronext Exchange or OTC Markets. The media release is in accordance with International Reporting Standard: Rule 12g3-2(b) under the Securities Exchange Act ('Rule 12g3-2(b)') permits non-U.S. companies with securities listed primarily on a Qualified Foreign Exchange to make publicly available to U.S investors in English the same information that is made publicly available in their home countries as an alternative to SEC reporting Exchange Act Rule 12g3-2(b).